Sprout Pharmaceuticals, Inc., the manufacturer of ADDYI® (flibanserin), is conducting the ADDYI Pregnancy Registry (Study). This is an observational study to collect pregnancy-related health outcomes of women who have taken at least 1 dose of ADDYI at any time during their pregnancy, compared to women who have never taken ADDYI or who stopped taking ADDYI at least one month prior to pregnancy. In addition, infant health outcomes including major congenital anomalies, postnatal growth, and development will be collected up to the infant's first birthday.
You are being asked to participate in this observational study because you are pregnant and have taken at least one dose of ADDYI at any time during your pregnancy, or you are pregnant and have not taken a dose of ADDYI or stopped taking ADDYI at least one month before becoming pregnant.
If you are able and willing to provide consent for the Study either verbally or electronically, you may be eligible to participate in either of the two scenarios outlined below:
You have taken at least one dose of ADDYI at any time during your pregnancy, defined as any time from one month prior to pregnancy through the end of pregnancy
You are pregnant and have never taken a dose of ADDYI or stopped taking ADDYI at least one month prior to becoming pregnant
The following options are available if you
would like to learn more about the Study or are
interested in enrolling in the Study:
Hours of operation:
Monday - Friday
8:00 a.m. to 5:00 p.m. Eastern Time
Email: AddyiPregnancy@ubc.comReport a Pregnancy
Notify your healthcare provider right away if you become pregnant or plan to become pregnant while on ADDYI.